Menu Search
Equities

H Lundbeck A/S

LUNA:VIE

H Lundbeck A/S

Actions
  • Price (EUR)4.91
  • Today's Change0.02 / 0.41%
  • Shares traded0.00
  • 1 Year change+21.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

  • Revenue in DKK (TTM)21.44bn
  • Net income in DKK2.69bn
  • Incorporated1950
  • Employees5.50k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		HLUN B:CPH since
announced		Transaction
value
Longboard Pharmaceuticals IncAnnounced14 Oct 202414 Oct 2024Announced-6.72%2.63bn
Data delayed at least 15 minutes, as of Nov 22 2024 16:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.